NIKKEI 225
37,552.16 +113.55 (+0.30%) HANG SENG
16,828.93 +317.24 (+1.92%) CRUDE OIL
83.05 +1.15 (+1.40%) GOLD FUTURES
2,341.80 -4.60 (-0.20%) DOW
38,491.99 +252.01 (+0.66%) Bitcoin GBP
53,573.16 +282.02 (+0.53%)
Novartis AG (0QLR.IL)
| Previous close | 86.12 |
| Open | 90.00 |
| Bid | 87.35 x N/A |
| Ask | 91.82 x N/A |
| Day's range | 88.92 - 92.00 |
| 52-week range | 79.36 - 233.50 |
| Volume | |
| Avg. volume | 1,925,459 |
| Market cap | 205.406B |
| Beta (5Y monthly) | 0.49 |
| PE ratio (TTM) | 27.91 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.20 (3.78%) |
| Ex-dividend date | 09 Mar 2023 |
| 1y target est | N/A |
- Yahoo Finance Video
Novartis raises full-year guidance on Q1 beat, drug sales
Shares of Novartis (NVS) are soaring in Tuesday's pre-market trading session — holding onto steady gains into the market open — after the Swiss pharmaceutical giant reported better-than-expected first-quarter earnings and raised its full-year guidance. The robust financial performance was driven primarily by strong sales of the company's innovative heart failure and psoriasis treatment drugs. Yahoo Finance Health Reporter Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Angel Smith
- Investor's Business Daily
How Novartis Rode Two Blockbuster Drugs To Its Beat And Raise, And Three-Day Sprint
Novartis stock jumped Tuesday after the drugmaker topped first-quarter sales and earnings forecasts, and raised its full-year outlook.
- Zacks
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
Incyte's (INCY) first-quarter 2024 revenues are likely to have been driven by the U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.
